Published in Br Med J on November 29, 1969
Chronic fenfluramine administration: some cerebral effects. Br Med J (1971) 1.45
CP-154,526, a CRF type-1 receptor antagonist, attenuates the cue-and methamphetamine-induced reinstatement of extinguished methamphetamine-seeking behavior in rats. Psychopharmacology (Berl) (2006) 1.06
Release by amphetamine in man of growth hormone and corticosteroids: the effects of thymoxamine and propranolol. Br J Pharmacol (1970) 0.91
Effect of fenfluramine on human growth hormone release. Br Med J (1973) 0.79
Effects of catecholamines on secretion of adrenocorticotrophic hormone (ACTH) in man. J Clin Pathol (1987) 0.77
Amphetamines, growth hormone and narcolepsy. Br J Clin Pharmacol (1977) 0.76
Response to stress. Br Med J (1970) 0.75
A simple fluorimetric method for the estimation of free 11-hydroxycorticoids in human plasma. J Clin Pathol (1962) 18.80
A radio-immunoelectrophoretic assay for human growth hormone. Biochem J (1964) 3.29
The effect of some sympathomimetic amines on the ascorbic acid content of rats' adrenal glands. J Physiol (1949) 1.91
Adrenergic receptor control mechanism for growth hormone secretion. J Clin Invest (1968) 1.60
The effect of adrenocorticotrophic hormone (ACTH) on avoidance conditioning in the rat. J Comp Physiol Psychol (1955) 1.24
Enhancement of human performance by caffeine and the amphetamines. Pharmacol Rev (1962) 1.17
Cholinergic and monoaminergic pathways in the hypothalamus. Br Med Bull (1966) 1.14
The effect of adrenocorticotropic hormone in epilepsy. J Pediatr (1950) 1.12
DIFFERENTIAL EFFECTS OF TWO AMPHETAMINE-BARBITURATE MIXTURES IN MAN. Br J Pharmacol Chemother (1965) 1.03
EFFECT OF DRUGS ON METABOLISM OF CATECHOLAMINES IN THE BRAIN. Br Med Bull (1965) 0.90
Hypoglycemia, stress and growth hormone release: blockade of growth hormone release by drugs acting on the central nervous system. Endocrinology (1967) 0.90
Changes in plasma cortisol induced by dexamphetamine and chlordiazepoxide given alone and in combination in man. J Endocrinol (1968) 0.90
[The interaction of chlordiazepoxide and dexamphetamine in man]. Therapie (1968) 0.89
Psychological effects of centrally acting drugs in man; effects of chlorpromazine secobarbital on visual and motor behaviour. J Ment Sci (1958) 0.86
The anorectic effect of dexamphetamine sulphate. Br J Pharmacol Chemother (1968) 0.83
Role of adrenergic and cholinergic structures in the control of the pituitary-adrenal system. Endocrinology (1967) 0.82
Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. Arch Clin Neuropsychol (1999) 4.38
Thyrotrophin-releasing hormone as a thyroid-function test. Lancet (1971) 4.34
The thyrotrophin-releasing hormone test in diseases of the pituitary and hypothalamus. Lancet (1972) 3.10
Early treatment with allopurinol in familial juvenile hyerpuricaemic nephropathy (FJHN) ameliorates the long-term progression of renal disease. QJM (2002) 3.09
HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet (2002) 3.07
The plasma sugar, free fatty acid, cortisol, and growth hormone response to insulin. I. In control subjects. J Clin Invest (1966) 2.92
Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Lancet (1974) 2.65
Threshold adrenocortical sensitivity in man and its possible application to corticotrophin bioassay. Lancet (1967) 2.44
Vasopressin analogue DDAVP in diabetes insipidus: clinical and laboratory studies. Br Med J (1973) 2.41
Adrenocorticotrophic action of long-acting tetracosactrin compared with corticotrophin-gel. Br Med J (1967) 2.39
A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing's disease and the occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab (1999) 2.30
Long-term treatment of acromegaly with bromocriptine. Br Med J (1977) 2.18
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med (2000) 2.16
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet (2001) 2.08
Galactorrhoea: successful treatment with reduction of plasma prolactin levels by brom-ergocryptine. Br Med J (1972) 2.07
Corticosteroid treatment and surgery. 1. An investigation of the indications for steroid cover. Anaesthesia (1969) 2.00
Long-term treatment of galactorrhoea and hypogonadism with bromocriptine. Br Med J (1974) 1.98
Social and environmental factors and life expectancy, infant mortality, and maternal mortality rates: results of a cross-national comparison. Soc Sci Med (1994) 1.97
Increased beta-endorphin but not met-enkephalin levels in human cerebrospinal fluid after acupuncture for recurrent pain. Lancet (1980) 1.94
Cloning and characterization of cDNAs encoding human gastrin-releasing peptide. Proc Natl Acad Sci U S A (1984) 1.93
Clinical studies of multiple endocrine neoplasia type 1 (MEN1) QJM (1996) 1.93
The frequency and distribution of spontaneous attention shifts between social and nonsocial stimuli in autistic, typically developing, and nonautistic developmentally delayed infants. J Child Psychol Psychiatry (1998) 1.91
A detailed investigation of circulating IgE levels in a normal population. Clin Allergy (1975) 1.89
Integrated medicine. BMJ (2001) 1.85
Children with autism show local precedence in a divided attention task and global precedence in a selective attention task. J Child Psychol Psychiatry (1999) 1.76
Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients. Lancet (1974) 1.71
Bromocriptine treatment of acromegaly. Br Med J (1975) 1.70
Transsphenoidal resection in Cushing's disease: undetectable serum cortisol as the definition of successful treatment. Clin Endocrinol (Oxf) (1993) 1.69
Gradual reintroduction of full-strength milk after acute gastroenteritis in children. Lancet (1979) 1.69
Action of growth-hormone-release inhibitory hormone in healthy men and in acromegaly. Lancet (1973) 1.68
Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer. Br Med J (Clin Res Ed) (1983) 1.67
Luteinizing hormone and follicle stimulating hormone-releasing hormone test in patients with hypothalamic-pituitary-gonadal dysfunction. Br Med J (1973) 1.66
Diagnosis and management of ACTH-dependent Cushing's syndrome: comparison of the features in ectopic and pituitary ACTH production. Clin Endocrinol (Oxf) (1986) 1.62
Apathetic T-3 toxicosis. Br Med J (1974) 1.61
Interaction between secretion of the gonadotrophins, prolactin, growth hormone, thyrotrophin and corticosteroids in man: the effects of LH FSH-RH, TRH and hypoglycaemia alone and in combination. Clin Endocrinol (Oxf) (1973) 1.60
Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet (1998) 1.59
Does oral folic acid lower total homocysteine levels and improve endothelial function in children with chronic renal failure? Circulation (2002) 1.58
A rapid radioimmunoassay for human chorionic somatomammotrophin. J Obstet Gynaecol Br Commonw (1971) 1.54
Hypothalamo-pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment. J Clin Endocrinol Metab (2000) 1.52
Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. N Engl J Med (1989) 1.52
Pituitary-adrenal function in severe depressive illness. Lancet (1968) 1.52
Hyponatraemia in the first week of life in preterm infants. Part I. Arginine vasopressin secretion. Arch Dis Child (1984) 1.52
Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. J Clin Invest (1995) 1.49
Bromocriptine treatment of female infertility: report of 13 pregnancies. Br Med J (1975) 1.49
Letter: Metaclopramide and prolactin. Br Med J (1974) 1.48
Frasier syndrome, part of the Denys Drash continuum or simply a WT1 gene associated disorder of intersex and nephropathy? Clin Endocrinol (Oxf) (2000) 1.48
A fundamental defect of adrenocortical control in Cushing's disease. J Endocrinol (1968) 1.46
Plasma prolactin activity in inappropriate lactation. Br Med J (1971) 1.46
Immunoreactive corticotrophin levels in adrenocortical insufficiency. Br Med J (1971) 1.46
A stable, nonsense mutation associated with a case of infantile onset polycystic kidney disease 1 (PKD1). Hum Mol Genet (1996) 1.45
Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study. Clin Endocrinol (Oxf) (2000) 1.45
Spontaneous clinical improvement in dense deposit disease. Pediatr Nephrol (2000) 1.45
Cushing's syndrome. Clin Endocrinol Metab (1985) 1.44
Colorectal neoplasia in acromegaly. Gut (1999) 1.42
Lymphocytic hypophysitis: unusual features of a rare disorder. Clin Endocrinol (Oxf) (1995) 1.41
The relationship between serum prolactin and immunocytochemical staining for prolactin in patients with pituitary macroadenomas. Clin Endocrinol (Oxf) (1985) 1.40
Late diagnosis of pituitary and parapituitary lesions causing visual failure. Br Med J (Clin Res Ed) (1986) 1.40
The release of leptin and its effect on hormone release from human pituitary adenomas. Clin Endocrinol (Oxf) (2001) 1.39
Identification of olfactory dysfunction in carriers of X-linked Kallmann's syndrome. Clin Endocrinol (Oxf) (1994) 1.39
Pituitary peptide. Nat New Biol (1973) 1.39
The neuroradiology of Kallmann's syndrome: a genotypic and phenotypic analysis. J Clin Endocrinol Metab (1996) 1.38
Bilateral testicular tumours in congenital adrenal hyperplasia: a continuing diagnostic and therapeutic dilemma. Clin Endocrinol (Oxf) (1989) 1.38
Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab (2001) 1.37
Bromocriptine in management of large pituitary tumours. Br Med J (Clin Res Ed) (1982) 1.36
The development of a radioimmunoassay for oxytocin: the extraction of oxytocin from plasma, and its measurement during parturition in human and goat blood. J Endocrinol (1970) 1.35
Outcome and growth of infants with severe chronic renal failure. Kidney Int (2000) 1.33
Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. Am J Hum Genet (1995) 1.32
Prolactinomas. Br Med J (Clin Res Ed) (1985) 1.32
Plasma-cortisol response to lysine-vasopressin. Comparison with other tests of human pituitary-adrenocortical function. Lancet (1965) 1.31
Development of a specific extracted radioimmunoassay for methionine enkephalin in human plasma and cerebrospinal fluid. J Endocrinol (1980) 1.31
A rapid semi-automated method for the measurement of human chorionic somatomammotrophin. The normal range in the third trimester and its relation to fetal weight. J Obstet Gynaecol Br Commonw (1971) 1.30
Development and validation of a radioimmunoassay for peptides related to beta-melanocyte-stimulating hormone in human plasma: the lipotropins. J Clin Endocrinol Metab (1975) 1.30
Radioimmunoassay for determining plasms-levels of angiotensin II in man. Lancet (1967) 1.29
Polarisation fluoroimmunoassay of gentamicin. Clin Chim Acta (1976) 1.27
Development and validation of a specific radioimmunoassay for somatostatin in human plasma. Ann Clin Biochem (1979) 1.26
Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography. Eur J Endocrinol (2003) 1.26
beta-Endorphin in human cerebrospinal fluid. Lancet (1978) 1.26
Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab (2000) 1.26
Amenorrhoea, galactorrhoea, and primary hypothyroidism with high circulating levels of prolactin. Br Med J (1971) 1.25
Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int (1997) 1.24
Growth hormone release inhibiting hormone in acromegaly. Br Med J (1974) 1.24
Placental lactogen levels as guide to outcome of threatened abortion. Br Med J (1972) 1.24
The physician-delivered smoking intervention project: can short-term interventions produce long-term effects for a general outpatient population? Health Psychol (1994) 1.24
Met-enkephalin circulates in human plasma. Nature (1980) 1.23
C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta (1985) 1.22
Acupuncture in heroin addicts; changes in Met-enkephalin and beta-endorphin in blood and cerebrospinal fluid. Lancet (1979) 1.22
Tumor and plasma ACTH concentrations in patients with and without the ectopic ACTH syndrome. Clin Endocrinol (Oxf) (1972) 1.21
Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. Br Med J (Clin Res Ed) (1985) 1.19
Metyrapone in long-term management of Cushing's disease. Br Med J (1977) 1.19
Galactorrhoea. Br Med J (1972) 1.19
Hormonal and metabolic responses to an enkephalin analogue in normal man. Lancet (1978) 1.18
Angiotropic large cell lymphoma (ALCL): morphological, immunohistochemical and genotypic studies with analysis of previous reports. Hematol Oncol (1989) 1.18
Dissociation of the disappearance of bioactive and radioimmunoreactive ACTH from plasma in man. J Clin Endocrinol Metab (1971) 1.18
Hormonal responses to synthetic luteinizing hormone and follicle stimulating hormone-releasing hormone in man. Br Med J (1972) 1.17
Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clin Endocrinol (Oxf) (2000) 1.17